Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
2021
Authors:
Mansilla, M. J.Presas-Rodríguez, S.
Teniente-Serra, A.
González-Larreategui, I.
Quirant-Sánchez, B.
Fondelli, F.
Nikolovski, Neda
Iwaszkiewicz-Grześ, D.
Chwojnicki, K.
Miljković, Đorđe
Trzonkowski, P.
Ramo-Tello, C.
Martínez-Cáceres, E. M.
Document Type:
Review (Published version)
Metadata
Show full item recordAbstract:
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. Hence, there is an urgent need for the development of next-generation treatments that, alone or in combination, stop the undesired autoimmune response and contribute to the restoration of homeostasis. This review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients (tolerogenic dendritic cells, regulatory T cells, mesenchymal stem cells, and vaccination with T cells). Data collected from preclinical studies performed in the experimental autoimmune encephalomyelitis (EAE) model of MS in animals, in vitro cultures of cells from MS patients and the initial results of phase I/II clinical trials are analyzed to better understand which parameters are relevant for obtaining an efficient cell-based therapy for MS.
Keywords:
Autoimmunity; Cell-based therapy; Multiple sclerosis; Neuroprotection; ToleranceSource:
Cellular and Molecular Immunology, 2021, 18, 6, 1353-1374Funding / projects:
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200007 (University of Belgrade, Institute for Biological Research 'Siniša Stanković') (RS-MESTD-inst-2020-200007)
- STRATEGMED1/233368/1/NCBR/2014
- INsTRuCT Consortium from the European Union Horizon 2020 Programme
DOI: 10.1038/s41423-020-00618-z
ISSN: 1672-7681
PubMed: 33958746